Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 172

1.

Novel, gross chromosomal alterations involving PTEN cooperate with allelic loss in prostate cancer.

Reid AH, Attard G, Brewer D, Miranda S, Riisnaes R, Clark J, Hylands L, Merson S, Vergis R, Jameson C, Høyer S, Sørenson KD, Borre M, Jones C, de Bono JS, Cooper CS.

Mod Pathol. 2012 Jun;25(6):902-10. doi: 10.1038/modpathol.2011.207. Epub 2012 Mar 30.

2.

Integrated analysis of the genomic instability of PTEN in clinically insignificant and significant prostate cancer.

Murphy SJ, Karnes RJ, Kosari F, Castellar BE, Kipp BR, Johnson SH, Terra S, Harris FR, Halling GC, Klein JL, Nasir A, Bergstrahl E, Rangel LJ, Sukov WR, Vasmatzis G, Cheville JC.

Mod Pathol. 2016 Feb;29(2):143-56. doi: 10.1038/modpathol.2015.136. Epub 2015 Nov 27.

3.

PTEN losses exhibit heterogeneity in multifocal prostatic adenocarcinoma and are associated with higher Gleason grade.

Yoshimoto M, Ding K, Sweet JM, Ludkovski O, Trottier G, Song KS, Joshua AM, Fleshner NE, Squire JA, Evans AJ.

Mod Pathol. 2013 Mar;26(3):435-47. doi: 10.1038/modpathol.2012.162. Epub 2012 Sep 28.

4.

PTEN genomic deletion is an early event associated with ERG gene rearrangements in prostate cancer.

Bismar TA, Yoshimoto M, Vollmer RT, Duan Q, Firszt M, Corcos J, Squire JA.

BJU Int. 2011 Feb;107(3):477-85. doi: 10.1111/j.1464-410X.2010.09470.x.

5.

High nuclear karyopherin α 2 expression is a strong and independent predictor of biochemical recurrence in prostate cancer patients treated by radical prostatectomy.

Grupp K, Habermann M, Sirma H, Simon R, Steurer S, Hube-Magg C, Prien K, Burkhardt L, Jedrzejewska K, Salomon G, Heinzer H, Wilczak W, Kluth M, Izbicki JR, Sauter G, Minner S, Schlomm T, Tsourlakis MC.

Mod Pathol. 2014 Jan;27(1):96-106. doi: 10.1038/modpathol.2013.127. Epub 2013 Jul 26.

6.

Detection of ERG gene rearrangements and PTEN deletions in unsuspected prostate cancer of the transition zone.

Liu S, Yoshimoto M, Trpkov K, Duan Q, Firszt M, Corcos J, Squire JA, Bismar TA.

Cancer Biol Ther. 2011 Mar 15;11(6):562-6. Epub 2011 Mar 15.

PMID:
21178509
7.

Fluorescence in situ hybridization study shows association of PTEN deletion with ERG rearrangement during prostate cancer progression.

Han B, Mehra R, Lonigro RJ, Wang L, Suleman K, Menon A, Palanisamy N, Tomlins SA, Chinnaiyan AM, Shah RB.

Mod Pathol. 2009 Aug;22(8):1083-93. doi: 10.1038/modpathol.2009.69. Epub 2009 May 1.

8.

Assessing the order of critical alterations in prostate cancer development and progression by IHC: further evidence that PTEN loss occurs subsequent to ERG gene fusion.

Gumuskaya B, Gurel B, Fedor H, Tan HL, Weier CA, Hicks JL, Haffner MC, Lotan TL, De Marzo AM.

Prostate Cancer Prostatic Dis. 2013 Jun;16(2):209-15. doi: 10.1038/pcan.2013.8. Epub 2013 Apr 2.

9.

Novel dual-color immunohistochemical methods for detecting ERG-PTEN and ERG-SPINK1 status in prostate carcinoma.

Bhalla R, Kunju LP, Tomlins SA, Christopherson K, Cortez C, Carskadon S, Siddiqui J, Park K, Mosquera JM, Pestano GA, Rubin MA, Chinnaiyan AM, Palanisamy N.

Mod Pathol. 2013 Jun;26(6):835-48. doi: 10.1038/modpathol.2012.234. Epub 2013 Jan 25.

10.

Heterogeneity and chronology of PTEN deletion and ERG fusion in prostate cancer.

Krohn A, Freudenthaler F, Harasimowicz S, Kluth M, Fuchs S, Burkhardt L, Stahl P, C Tsourlakis M, Bauer M, Tennstedt P, Graefen M, Steurer S, Sirma H, Sauter G, Schlomm T, Simon R, Minner S.

Mod Pathol. 2014 Dec;27(12):1612-20. doi: 10.1038/modpathol.2014.70. Epub 2014 Apr 25.

11.

Analytic validation of a clinical-grade PTEN immunohistochemistry assay in prostate cancer by comparison with PTEN FISH.

Lotan TL, Wei W, Ludkovski O, Morais CL, Guedes LB, Jamaspishvili T, Lopez K, Hawley ST, Feng Z, Fazli L, Hurtado-Coll A, McKenney JK, Simko J, Carroll PR, Gleave M, Lin DW, Nelson PS, Thompson IM, True LD, Brooks JD, Lance R, Troyer D, Squire JA.

Mod Pathol. 2016 Aug;29(8):904-14. doi: 10.1038/modpathol.2016.88. Epub 2016 May 13.

12.

Loss of PTEN is associated with aggressive behavior in ERG-positive prostate cancer.

Leinonen KA, Saramäki OR, Furusato B, Kimura T, Takahashi H, Egawa S, Suzuki H, Keiger K, Ho Hahm S, Isaacs WB, Tolonen TT, Stenman UH, Tammela TL, Nykter M, Bova GS, Visakorpi T.

Cancer Epidemiol Biomarkers Prev. 2013 Dec;22(12):2333-44. doi: 10.1158/1055-9965.EPI-13-0333-T. Epub 2013 Oct 1.

13.

Aquaporin 5 expression is frequent in prostate cancer and shows a dichotomous correlation with tumor phenotype and PSA recurrence.

Pust A, Kylies D, Hube-Magg C, Kluth M, Minner S, Koop C, Grob T, Graefen M, Salomon G, Tsourlakis MC, Izbicki J, Wittmer C, Huland H, Simon R, Wilczak W, Sauter G, Steurer S, Krech T, Schlomm T, Melling N.

Hum Pathol. 2016 Feb;48:102-10. doi: 10.1016/j.humpath.2015.09.026. Epub 2015 Oct 22.

PMID:
26614400
14.

βIII-tubulin overexpression is an independent predictor of prostate cancer progression tightly linked to ERG fusion status and PTEN deletion.

Tsourlakis MC, Weigand P, Grupp K, Kluth M, Steurer S, Schlomm T, Graefen M, Huland H, Salomon G, Steuber T, Wilczak W, Sirma H, Simon R, Sauter G, Minner S, Quaas A.

Am J Pathol. 2014 Mar;184(3):609-17. doi: 10.1016/j.ajpath.2013.11.007. Epub 2013 Dec 28.

PMID:
24378408
15.

Genomic deletion of PTEN is associated with tumor progression and early PSA recurrence in ERG fusion-positive and fusion-negative prostate cancer.

Krohn A, Diedler T, Burkhardt L, Mayer PS, De Silva C, Meyer-Kornblum M, Kötschau D, Tennstedt P, Huang J, Gerhäuser C, Mader M, Kurtz S, Sirma H, Saad F, Steuber T, Graefen M, Plass C, Sauter G, Simon R, Minner S, Schlomm T.

Am J Pathol. 2012 Aug;181(2):401-12. doi: 10.1016/j.ajpath.2012.04.026. Epub 2012 Jun 13.

PMID:
22705054
16.

Single-cell genetic analysis reveals insights into clonal development of prostate cancers and indicates loss of PTEN as a marker of poor prognosis.

Heselmeyer-Haddad KM, Berroa Garcia LY, Bradley A, Hernandez L, Hu Y, Habermann JK, Dumke C, Thorns C, Perner S, Pestova E, Burke C, Chowdhury SA, Schwartz R, Schäffer AA, Paris PL, Ried T.

Am J Pathol. 2014 Oct;184(10):2671-86. doi: 10.1016/j.ajpath.2014.06.030. Epub 2014 Aug 14.

17.

Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer.

Reid AH, Attard G, Ambroisine L, Fisher G, Kovacs G, Brewer D, Clark J, Flohr P, Edwards S, Berney DM, Foster CS, Fletcher A, Gerald WL, Møller H, Reuter VE, Scardino PT, Cuzick J, de Bono JS, Cooper CS; Transatlantic Prostate Group.

Br J Cancer. 2010 Feb 16;102(4):678-84. doi: 10.1038/sj.bjc.6605554. Epub 2010 Jan 26.

18.

Prevalence of TMPRSS2-ERG and SLC45A3-ERG gene fusions in a large prostatectomy cohort.

Esgueva R, Perner S, J LaFargue C, Scheble V, Stephan C, Lein M, Fritzsche FR, Dietel M, Kristiansen G, Rubin MA.

Mod Pathol. 2010 Apr;23(4):539-46. doi: 10.1038/modpathol.2009.193. Epub 2010 Jan 29.

19.

The prognostic value of SUMO1/Sentrin specific peptidase 1 (SENP1) in prostate cancer is limited to ERG-fusion positive tumors lacking PTEN deletion.

Burdelski C, Menan D, Tsourlakis MC, Kluth M, Hube-Magg C, Melling N, Minner S, Koop C, Graefen M, Heinzer H, Wittmer C, Sauter G, Simon R, Schlomm T, Steurer S, Krech T.

BMC Cancer. 2015 Jul 23;15:538. doi: 10.1186/s12885-015-1555-8.

20.

Interactions and relationships of PTEN, ERG, SPINK1 and AR in castration-resistant prostate cancer.

Bismar TA, Yoshimoto M, Duan Q, Liu S, Sircar K, Squire JA.

Histopathology. 2012 Mar;60(4):645-52. doi: 10.1111/j.1365-2559.2011.04116.x. Epub 2012 Jan 19.

PMID:
22260502

Supplemental Content

Support Center